Darolutamide Gains FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer Following ARANOTE Trial Success
核心洞察
Darolutamide (Nubeqa) received FDA approval on June 3, 2025, for treating metastatic hormone-sensitive prostate cancer (搜索) based on the ARANOTE trial results.
The ARANOTE trial demonstrated efficacy of darolutamide plus androgen deprivation therapy (搜索) as a doublet regimen, expanding treatment options beyond existing triplet therapies.
NCCN (搜索) guidelines now include four Category 1 preferred oral agents for mHSPC: abiraterone, apalutamide, enzalutamide, with darolutamide expected to be upgraded from Category 2B status.
Darolutamide (Nubeqa) has received FDA approval for the treatment of metastatic hormone-sensitive prostate cancer (搜索) (mHSPC), marking a significant expansion in oral treatment options for patients with this condition. The approval, granted on June 3, 2025, was based on results from the ARANOTE trial (NCT04736199), which evaluated darolutamide in combination with androgen deprivation therapy (搜索) (ADT).
ARANOTE Trial Establishes Efficacy Profile
The ARANOTE trial was conducted globally and demonstrated the efficacy of darolutamide plus ADT as a doublet regimen in mHSPC patients. According to Dr. Tian Zhang from UT Southwestern Medical Center (搜索), the trial's primary endpoint was radiographic progression-free survival, with overall survival as a secondary endpoint. While the hazard ratio for overall survival crossed 1.0, Dr. Zhang noted that "at the time of the initial presentation in 2024 for ARANOTE, not enough events had occurred in the OS end point to make a difference."
The ARANOTE trial represents the most recent addition to the evolving landscape of mHSPC treatments, following earlier landmark studies that established the current standard of care. The trial's design focused on darolutamide and ADT without requiring concurrent chemotherapy, distinguishing it from triplet regimens that include docetaxel.
Expanding Treatment Algorithm
The approval significantly impacts current treatment guidelines for mHSPC. Dr. Jahan Aghalar from New York Cancer and Blood Specialists (搜索) explained that the NCCN (搜索) guidelines now recommend three Category 1 oral agents in addition to ADT: abiraterone (Zytiga), apalutamide (Erleada), and enzalutamide (Xtandi). Darolutamide currently holds a Category 2B recommendation, though Dr. Zhang indicated that "with the recent approval and with the ARANOTE data, darolutamide will probably come up from a Category 2b indication."
This expansion is particularly relevant for patients with low-volume, metachronous metastases who prefer oral treatment options while minimizing adverse events. The case presented involved a 67-year-old patient who developed metastatic disease 13 months after radical prostatectomy, with imaging showing multiple enlarged retroperitoneal lymph nodes and three metastatic bone lesions.
Clinical Trial Timeline and Development
The development of oral agents for mHSPC has followed a systematic progression over the past decade. The LATITUDE trial (NCT01715285) began enrollment in 2013, establishing abiraterone's efficacy. Subsequently, the ENZAMET trial (NCT02446405) and ARCHES trial (NCT02677896) demonstrated enzalutamide's benefits, while the TITAN study (NCT03978988) validated apalutamide's role.
The ARASENS trial (NCT02799602) initially established darolutamide's efficacy in a triplet regimen with docetaxel and ADT in the post-LATITUDE era. Dr. Zhang noted that "ADT, darolutamide, and docetaxel came in the post-LATITUDE era" and that the ARASENS regimen received approval in 2022.
Comparative Efficacy Across Trials
The efficacy profiles across major mHSPC trials show consistent benefits with oral agents. Abiraterone doublets demonstrated median radiographic progression-free survival around 33 months with overall survival improvement for both high-volume and low-volume disease in LATITUDE. The ENZAMET and ARCHES trials with enzalutamide showed improvements in both radiographic progression-free survival and overall survival.
Dr. Aghalar highlighted that trials demonstrating statistically significant overall survival benefits included LATITUDE, STAMPEDE, ENZAMET, and TITAN. For ARCHES, the overall survival benefit was statistically significant with a hazard ratio of 0.66, while ARANOTE showed a hazard ratio of 0.81, which was not statistically significant.
Treatment Considerations and Patient Selection
The approval provides additional flexibility in treatment selection, particularly for patients seeking oral therapy with manageable adverse event profiles. According to the treatment algorithm, patients are generally treated until intolerable toxicity or progression occurs, after which they transition to further lines of therapy in the castration-resistant setting.
The expanding oral treatment options address the complexity that has emerged in prostate cancer (搜索) management, with distinctions between high-volume and low-volume disease, as well as synchronous versus metachronous metastases. Dr. Aghalar noted that "prostate cancer has become a bit more complicated than how it was 15 years ago" due to these clinical classifications and the growing number of effective treatment combinations.
Both darolutamide and abiraterone have demonstrated good phase 3 data for triplet regimens, with the PEACE-1 trial (NCT01957436) also showing positive results for abiraterone, docetaxel, and ADT combinations reported in 2024.